TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1281362
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH; Sandoparin) administered once daily subcutaneously at a fixed dosage
Study: 1281362
Drug: Dextran 70
Normalized name: Dextran 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran 70 administered intravenously
Study: 1281362
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) and Dextran 70
Study: 31533277
Drug: 15 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 µg dose of VLP vaccine
Study: 31533277
Drug: 45 µg
Normalized name: tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45 µg dose of VLP vaccine
Study: 25580784
Drug: Topical betamethasone
Normalized name: betamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betamethasone for RAS (Control)
Study: 22226929
Drug: firategrast 900
Normalized name: Firategrast
DrugBank: Firategrast (DB12732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: firategrast 900 mg or 1200 mg
Study: 22226929
Drug: firategrast 600
Normalized name: Firategrast
DrugBank: Firategrast (DB12732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: firategrast 600 mg
Study: 22226929
Drug: firategrast 150
Normalized name: Firategrast
DrugBank: Firategrast (DB12732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: firategrast 150 mg
Study: 15889358
Drug: Amoxicillin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (1000 mg 3 times per day) for patients with positive urinary antigen test results
Study: 15889358
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg 2 times per day) for patients with negative urinary antigen test results
Study: 12479768
Drug: Standardized HRQL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized HRQL assessments (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐Core 30)
Study: 8592955
Drug: Thiazide diuretic
Normalized name: Thiazide diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretic use
Study: 2696507
Drug: IV labetalol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV labetalol, 0.25 mg/kg
Study: 2696507
Drug: IV labetalol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV labetalol, 0.75 mg/kg
Study: 18493
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day clobazam (HR 376)
Study: 18493
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day diazepam
Study: 19387874
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention + Metformin (1500 g daily)
Study: 16711496
Drug: Continuous sciatic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous sciatic nerve block (0.5% ropivacaine, 20 mL, plus continuous infusion of 5 mL/h)
Study: 16711496
Drug: Single-dose sciatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose sciatic nerve block (20 mL of 0.5% ropivacaine)
Study: 14709300
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac sodium 0.1% solution (Voltaren Ophthalmic)
Study: 14709300
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac tromethamine 0.5% solution (Acular)
Study: 9036608
Drug: EHF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHF therapy alone (group 1)
Study: 9036608
Drug: EHF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHF therapy plus antibacterial drugs (group 2)
Study: 3979723
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g protein meal
Study: 3979723
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g protein meal
Study: 31102823
Drug: Antibiotic lock
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic lock solution (gentamicin 7 mg/ml + cefazolin 12 mg/ml + heparin 3500 IU/ml)
Study: 31102823
Drug: Lock solution
Normalized name: Defencath catheter lock solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lock solution with TauroLock-Hep500 (taurolidine citrate 4% + heparin 500 IU/ml)
Study: 29534661
Drug: Bortezomib (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (1 cycle at 1.3 mg/m2), methylprednisolone (500 mg/kg), 7 sessions of plasmapheresis, antithymocyte globulin (3-5 mg/kg/day for 10 days), rituximab (2 doses at 375 mg/m2)
Study: 29534661
Drug: Bortezomib-based treatment
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib-based treatment
Study: 26814104
Drug: Dexmedetomidine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.4 µg·kg(‐1)·h(‐1)
Study: 26814104
Drug: Dexmedetomidine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.6 µg·kg(‐1)·h(‐1)
Study: 26814104
Drug: Dexmedetomidine 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.8 µg·kg(‐1)·h(‐1)
Study: 26814104
Drug: Dexmedetomidine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1.0 µg·kg(‐1)·h(‐1)
Study: 26814104
Drug: Remifentanil 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.1 µg·kg(‐1)·min(‐1)
Study: 26814104
Drug: Dexmedetomidine 0.6-1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.6-1.0 µg·kg(‐1)·h(‐1)
Study: 26814104
Drug: Dexmedetomidine 0.4-0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.4-0.8 µg·kg(‐1)·h(‐1)
Study: 21680720
Drug: Autologous dendritic
Normalized name: COVID19 s-vax loaded autologous dendritic cell vaccine
DrugBank: COVID19 s-vax loaded autologous dendritic cell vaccine (DB15814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous dendritic cells administered intradermally (10 million cells, once every 2 weeks for 4 administrations)
Study: 12669389
Drug: Treatment methods
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment methods from randomized trials
Study: 12669389
Drug: Evidence-based medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based medicine
Study: 11595472
Drug: OCT (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCT (20 mg omeprazole + 2 x 250 mg clarithromycin + 2 x 500 mg tinidazole for 7 days)
Study: 11595472
Drug: OAM (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAM (20 mg omeprazole + 2 x 1000 mg amoxicillin + 2 x 500 mg metronidazole for 7 days)
Study: 11595472
Drug: PAC (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAC (40 mg pantoprazole + 2 x 1000 mg amoxicillin + 2 x 500 mg clarithromycin for 7 days)
Study: 11595472
Drug: RBC-C (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC-C (2 x 400 mg ranitidin bismuth citrate + 2 x 500 mg clarithromycin for 14 days)
Study: 11595472
Drug: LCM (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCM (2 x 30 mg lansoprazole + 2 x 250 mg clarithromycin + 2 x 500 mg metronidazole)
Study: 11595472
Drug: RBC-CM (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC-CM (2 x 400 mg ranitidin bismuth citrate + 2 x 250 mg clarithromycin + 2 x 500 mg metronidazole)
Study: 9402342
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with three drugs
Study: 9402342
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to VacA
Study: 9402342
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to CagA
Study: 8428859
Drug: Oral route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral route (OR)
Study: 3313099
Drug: L-baclofen
Normalized name: L-Baclofen
DrugBank: L-Baclofen (DB12098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-baclofen
Study: 29691197
Drug: Standard Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Medication Counseling (SMC)
Study: 27006332
Drug: Enzalutamide (160mg)
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide (160mg) once daily
Study: 24941010
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of insulin and glucose, titrated to preserve normoglycemia (3.5‐6.1 mmol L(‐1))
Study: 24941010
Drug: Standard metabolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard metabolic care (blood glucose 3.5‐10 mmol L(‐1))
Study: 21575130
Drug: N7-GP (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: N7-GP (dose of 12.5-100 μg kg(‐1))
Study: 12946546
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 2.0% ophthalmic solution
Study: 8403154
Drug: 2-Chloroprocaine 100
Normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-Chloroprocaine 100 mg
Study: 3437302
Drug: Clonazepam (0.5-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (0.5-2 mg per night)
Study: 29206813
Drug: Baclofen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (10 mg, t.i.d)
Study: 27881136
Drug: CHWs prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHWs prescribed artemisinin-based combination therapy (ACT)
Study: 31864376
Drug: Pre-referral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-referral treatment with rectal artesunate
Study: 1632534
Drug: Ketorolac (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (60 mg)
Study: 7893296
Drug: Meperidine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (75 mg)/Promethazine (25 mg)
Study: 30077530
Drug: Intensive PD
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive PD treatment (IPT)
Study: 30077530
Drug: Standard PD
Normalized name: PD-0299685
DrugBank: PD-0299685 (DB15264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PD treatment (CPT)
Study: 18498915
Drug: Valsartan/HCTZ combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/HCTZ combination therapy
Study: 22410289
Drug: Valsartan monotherapy
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan monotherapy
Study: 15948086
Drug: Scheduled telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled telephone calls by specially trained nurses promoting self‐management and guideline‐based therapy
Study: 12013192
Drug: d-alpha-tocopherol 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-alpha-tocopherol 1,200 I.U. daily
Study: 12013192
Drug: ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ascorbic acid 2 g daily
Study: 12013192
Drug: ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ascorbic acid 2 g plus d-alpha-tocopherol 1,200 I.U. daily
Study: 7772663
Drug: Propofol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.5 mg/kg followed by continuous infusion of 6 mg/kg/h, and alfentanil 15 micrograms/kg followed by continuous infusion of 15 micrograms/kg/h
Study: 444406
Drug: Chemotherapy (cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cyclophosphamide, vincristine, adriamycin and 5‐fluorouracil)
Study: 444406
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy (oophorectomy, tamoxifen or androgens)
Study: 444406
Drug: Other tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other tests (phytohaemagglutinin response, immunoglobulins G, A and M, or Mantoux test)
Study: 28052931
Drug: L.A.D.I.E.S. intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: L.A.D.I.E.S. intervention
Study: 20875219
Drug: Quetiapine-XR ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine-XR ≥ 300 mg/d
Study: 20875219
Drug: Quetiapine-XR (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine-XR (600 mg/d and 800 mg/d)
Study: 9692075
Drug: HRT (estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (estradiol valerate (2 mg) plus cyproterone acetate, 1 mg, sequentially: ClimenR)
Study: 9692075
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (16 women who refused all treatment)
Study: 7925172
Drug: Vigabatrin (gamma‐vinyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (gamma‐vinyl GABA; VGB) as add-on therapy
Study: 3294079
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (sham-bubble)
Study: 28444396
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment for at least 3 months
Study: 28444396
Drug: SDB patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDB patients (no CPAP treatment)
Study: 14967873
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g x d(‐1) Cr + 140 g x d(‐1) glucose for 7 days, followed by 5 g x d(‐1) Cr + 35 g x d(‐1) glucose for 21 days)
Study: 14967873
Drug: Placebo (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (160 g x d(‐1) glucose [loading] followed by 40 g x d(‐1) [maintenance])
Study: 11092065
Drug: Bromocriptine 2.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 2.50 mg
Study: 11092065
Drug: Bromocriptine 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 3.75 mg
Study: 1519828
Drug: Budesonide 0.8
Normalized name: DIAZOLIDINYL UREA 446 ug in 48 h / CLIOQUINOL 77 ug in 48 h / CHLORQUINALDOL 77 ug in 48 h / TIXOCORTOL PIVALATE 2 ug in 48 h / GOLD SODIUM THIOSULFATE 23 ug in 48 h / IMIDUREA 486 ug in 48 h / BUDESONIDE 0.8 ug in 48 h / HYDROCORTISONE BUTYRATE 16 ug in 48 h / 2-MERCAPTOBENZOTHIAZOLE 61 ug in 48 h / BACITRACIN 486 ug in 48 h / PARTHENOLIDE 2 ug in 48 h / DISPERSE BLUE 106 41 ug in 48 h / BRONOPOL 203 ug in 48 h CUTANEOUS PATCH [T.R.U.E. Test Panel 3.3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 0.8 mg twice daily for 14 days
Study: 6832199
Drug: Prajmalium bitartrate
Normalized name: prajmalium bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prajmalium bitartrate (PB) 80 mg/day for 4 days
Study: 6832199
Drug: Disopyramide 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide 400 mg/day for 4 days
Study: 30454846
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsule and gabapentin 900mg
Study: 16087941
Drug: Induction paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction paclitaxel (200 mg/m2)/carboplatin (AUC = 6) followed by TRT 63.0 Gy (arm 1, sequential)
Study: 16087941
Drug: Induction paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction paclitaxel (200 mg/m2)/carboplatin (AUC = 6) followed by weekly paclitaxel (45 mg/m2)/carboplatin (AUC = 2) with concurrent TRT 63.0 Gy (arm 2, induction/concurrent)
Study: 16087941
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (45 mg/m2)/carboplatin (AUC = 2)/TRT (63.0 Gy) followed by two cycles of paclitaxel (200 mg/m2)/carboplatin (AUC = 6; arm 3, concurrent/consolidation)
Study: 16087941
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (arms 1 and 2)
Study: 16087941
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (arms 2 and 3)
Study: 11583475
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg/kg/day for the first 3 days, 0.25 mg/kg/day for the next 3 days, and 0.125 mg/kg/day for the 7th day)
Study: 9826308
Drug: Bosentan 200
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan 200 mg IV
Study: 7926327
Drug: Selective dorsal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective dorsal rhizotomy (SDR) followed by one month of physical therapy at the center and a community physical therapy program
Study: 2688070
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg omeprazole once daily for 2 weeks
Study: 3512351
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg omeprazole once daily for 4 weeks
Study: 1106934
Drug: Carbamazepine (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (1,200 mg) and Phenytoin (300 mg)
Study: 1106934
Drug: Carbamazepine (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (1,200 mg) and Phenobarbital (300 mg)
Study: 1106934
Drug: Phenytoin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (300 mg) and Phenobarbital (300 mg)
Study: 1106934
Drug: Carbamazepine (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (1,200 mg), Phenytoin (300 mg), and Phenobarbital (300 mg)
Study: 1106934
Drug: Carbamazepine (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (1,200 mg)
Study: 1106934
Drug: Phenytoin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (300 mg)
Study: 1106934
Drug: Phenobarbital (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (300 mg)
Study: 295704
Drug: Oral prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prophylaxis
Study: 28329340
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg enteric-coated aspirin daily for 5 years
Study: 27611093
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (Control Group)
Study: 15041391
Drug: Muromonab (OKT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muromonab (OKT 3) + Neoral + adjunct + standard prednisone
Study: 15041391
Drug: Simulect +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulect + Neoral + adjunct + steroid sparing
Study: 15041391
Drug: Simulect +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulect + Neoral + adjunct + no prednisone
Study: 9738728
Drug: Montelukast (5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5-mg chewable tablet) once daily in the evening for 2 days
Study: 8281660
Drug: iohexol (low-osmolality
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol (low-osmolality contrast agent)
Study: 8281660
Drug: diatrizoate (high-osmolality
Approvals — FDA: no, EMA: no, PMDA: no
Description: diatrizoate (high-osmolality contrast agent)
Study: 8281660
Drug: Algorithm for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm for selective use of low-osmolality agents
Study: 15767771
Drug: 2% ketoconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% ketoconazole cream
Study: 26067687
Drug: Metformin (escalated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (escalated from 500 mg to 1000 mg twice daily)
Study: 21806596
Drug: Lifestyle treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle treatment
Study: 16805713
Drug: Isolated and
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated and adjuvant treatment of rhinitis and asthma
Study: 16805713
Drug: Clinical studies
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical studies regarding joint treatment
Study: 10921561
Drug: Intravenous erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous erythromycin (200 mg)
Study: 8609658
Drug: Chemotherapy (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (four courses of cisplatin [20 mg/m2] and fluorouracil [200 mg/m2], given daily for 5 consecutive days during weeks 1, 4, 7, and 10) plus radiotherapy (three courses of 20 Gy each, given in fractions of 2 Gy per day during weeks 2‐3, 5‐6, and 8‐9)
Study: 8609658
Drug: Radiotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy alone (70 Gy total dose, given in fractions of 2 Gy per day, 5 days per week)
Study: 3906674
Drug: Piretanide (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide (6 mg once daily)
Study: 3906674
Drug: Piretanide plus
Normalized name: piretanide
DrugBank: Piretanide (DB02925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide plus triamterene (6 mg + 50 mg once daily)
Study: 29097626
Drug: Standard carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard carbohydrate content (75 g, LCD)
Study: 29097626
Drug: Double carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double carbohydrate content (150 g, HCD)
Study: 25315409
Drug: 30mg morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg morphine hydrochloride
Study: 24597251
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg/d for six months
Study: 21990420
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of antiretroviral therapy (ART)
Study: 18671167
Drug: Four types
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four types of spoken sentences presented for immediate free recall: four short simple sentences, eight short simple sentences, four compound sentences, and four random word lists.
Study: 10622295
Drug: Infliximab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (3 mg/kg every 4 or 8 weeks)
Study: 10622295
Drug: Infliximab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (10 mg/kg every 4 or 8 weeks)
Study: 7572705
Drug: Carbohydrate restriction
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate restriction (84 h fasting with lipid emulsion infusion for 12-15 h each day)
Study: 1826506
Drug: Immunization with
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunization with type 3 pneumococcal vaccine
Study: 28640217
Drug: Total iodine
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total iodine intake (food and supplements)
Study: 28640217
Drug: Iodine-containing supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine-containing supplement intake